Down -12.14 percent in 4 Weeks, Heres Why Karyopharm Therapeutics Looks Ripe for a Turnaround

KPTI Stock  USD 0.60  0.02  3.23%   
Under 68% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
  
Karyopharm Therapeutics is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read at zacks.com
zacks News
  

Karyopharm Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Karyopharm Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Karyopharm Therapeutics Fundamental Analysis

We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Karyopharm Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Karyopharm Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.

Peers

Karyopharm Therapeutics Related Equities

MREOMereo BioPharma   12.39   
0%
100.0%
MRSNMersana Therapeutics   5.88   
0%
47.0%
NUVBNuvation Bio   5.62   
0%
45.0%
BLUEBluebird Bio   1.70   
0%
13.0%
NVCTNuvectis Pharma   1.53   
0%
12.0%
REPLReplimune   1.30   
0%
10.0%
ABOSAcumen Pharmaceuticals   1.13   
0%
9.0%
KRONKronos Bio   1.04   
8.0%
0%
GLUEMonte Rosa   1.26   
10.0%
0%
ASMBAssembly Biosciences   1.34   
10.0%
0%
CTMXCytomX Therapeutics   1.83   
14.0%
0%
GOSSGossamer Bio   2.33   
18.0%
0%
PMVPPmv Pharmaceuticals   2.65   
21.0%
0%
GBIOGeneration Bio   2.73   
22.0%
0%
AGIOAgios Pharm   3.28   
26.0%
0%
XFORX4 Pharmaceuticals   4.92   
39.0%
0%
RLYBRallybio Corp   5.49   
44.0%
0%
LYRALyra Therapeutics   5.56   
44.0%
0%
HOOKHookipa Pharma   6.40   
51.0%
0%

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories